2026-04-17T03:26:15Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/35192025-10-24T10:37:52Zcom_2072_378070com_2072_378040com_2072_378068col_2072_378092col_2072_378090

2025-10-24T10:37:52Z urn:hdl:11351/3519 Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database Real-Gatius, Jordi Serna-Arnaiz, Maria C. Forés, Rosa Pera, Guillem Ribes, Esther Alzamora, Maite Heras Tebar, Antonio Marsal Mora, Josep Ramon Morros, Rosa Giner-Soriano, Maria Malalties coronàries - Tractament Artèries - Malalties - Tractament Raonament basat en casos DISEASES::Cardiovascular Diseases::Vascular Diseases::Peripheral Vascular Diseases CHEMICALS AND DRUGS::Heterocyclic Compounds::Heterocyclic Compounds, Fused-Ring::Heterocyclic Compounds, 2-Ring::Purines::Purinones::Xanthines::Theobromine::Pentoxifylline ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Records as Topic::Medical Records::Medical Records Systems, Computerized::Electronic Health Records ENFERMEDADES::enfermedades cardiovasculares::enfermedades vasculares::enfermedades vasculares periféricas COMPUESTOS QUÍMICOS Y DROGAS::compuestos heterocíclicos::compuestos heterocíclicos con anillos de fusión::compuestos heterocíclicos de 2 anillos::purinas::purinonas::xantinas::teobromina::pentoxifilina TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros médicos::sistemas informatizados de historias clínicas::historias clínicas electrónicas Cilostazol; Peripheral artery disease; Primary healthcare Cilostazol ; Enfermedades Arteriales Periféricas; Atención primaria Cilostazol; Malalties arterials perifèriques; Atenció primària Background: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. Methods: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009–2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS). Results: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups. Conclusions: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients. 2025-10-24T10:37:52Z 2025-10-24T10:37:52Z 2018-06-18T09:37:49Z 2018-06-18T09:37:49Z 2018-05-08 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/3519 BMC Cardiovascular Disorders;18(1) https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-018-0822-4 Atribución-NoComercial-SinDerivadas 3.0 España http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess BioMed Central Scientia